UG

Shares of United-Guardian, Inc. UG have gained 2.3% since reporting results for the first quarter of 2026, outperforming the S&P 500 index’s 0.8% return. Over the past month, the stock has advanced 7.7% compared with the S&P 500’s 5% rise, reflecting stronger investor sentiment following the company’s quarterly update. United-Guardian reported first-quarter 2026 net sales of $2.87 million, up 15.8% from $2.48 million in the year-ago quarter. Net income climbed 46% year over year to $818,902 from $560,895, while earnings per share increased to 18 cents from 12 cents. Income from operations rose 5.2% to $642,449 despite higher operating costs. Total other income surged to $390,689 from $97,037 a year earlier, aided by settlement income tied to production disruptions involving a contract manufacturer. United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote The company attributed the quarter’s stronger performance primarily to higher sales in its pharmaceutical and cosmetic ingredients businesses. Pharmaceutical sales increased 24% year over year, driven largely by stronger demand for Renacidin, United-Guardian’s key pharmaceutical product. Management said efforts to increase market penetration and expand outreach for Renacidin contributed to the improvement. Cosmetic ingredient sales rose 21% from the prior-year period. The increase was mainly due to larger purchases from Ashland Specialty Ingredients (“ASI”), the company’s largest distributor of cosmetic ingredients. ASI purchases jumped 45% year over year after inventory reductions in 2025 had weighed on ordering activity. Domestic sales rose to $2.37 million from $1.76 million in the prior-year quarter, while export sales declined to about $499,000 from $725,000. As a result, domestic business represented about 83% of the total sales compared with roughly 71% a year earlier. Management also noted that the company continued expanding beyond its “natural” product portfolio during the quarter, with increased marketing efforts focused on pharmaceutical products and cosmetic preservatives. Cost of sales increased 28.9% year over year to $1.45 million, outpacing revenue growth due to a shift in product mix. Operating expenses rose 5.4% to $666,963, reflecting higher insurance and payroll-related costs. Research and development expenses were relatively stable at $115,021 compared with...

HAUPPAUGE, N.Y. (AP) — HAUPPAUGE, N.Y. (AP) — United-Guardian Inc. (UG) on Friday reported earnings of $819,000 in its first quarter. On a per-share basis, the Hauppauge, New York-based company said it had net income of 18 cents. The cosmetic ingredients maker posted revenue of $2.9 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UG at https://www.zacks.com/ap/UG

HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share). Donna Vigilante, President of United-Guardian, stated, “I am happy to report that sales and earnings increased in the first quarter of 2026 compared with the first quarter of 2025. Our financial performance was primarily driven by increased sales of both our pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose by 24% in the first quarter of 2026, driven primarily by increased demand for Renacidin®, our most important pharmaceutical product. Sales of our cosmetic ingredients increased by 21%, with the increase primarily attributable to an increase in purchases by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). ASI’s purchases increased by 45% in the first quarter of 2026 compared with the first quarter of 2025. The lower purchases by ASI in 2025 were primarily the result of ASI carrying excess inventory, which suppressed its purchase levels. This excess inventory has now been worked off, and they have resumed regular purchase levels.” “In addition to the increase in sales, our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer (“CM”) of Renacidin in connection with an unexpected shutdown at the CM’s facility in late 2023, which resulted in lost Renacidin sales.” “With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our “natural” product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026.” United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “saf...

Shares of United-Guardian, Inc. UG have gained 6.3% since the company reported its earnings for 2025, outperforming the broader market as the S&P 500 declined 1.7% over the same period. Over the past month, the stock has risen 2.3%, again showing relative strength compared with the S&P 500’s steeper 7.6% decline. United-Guardian reported weaker financial results for 2025 compared with 2024, with both revenues and earnings declining. Net sales fell 13% year over year to $10.55 million from $12.18 million. Net income dropped sharply to $2.11 million from $3.25 million in the prior year, representing a decline of roughly 35%. Earnings per share followed a similar trajectory, decreasing to 46 cents from 71 cents. Operating income also contracted significantly, falling to $2.24 million from $3.65 million in 2024, reflecting lower sales volumes and a modest rise in operating expenses. United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote A closer look at cost structures shows some mixed trends. Total costs and expenses declined slightly to $8.30 million from $8.54 million, primarily due to a reduction in cost of sales, which fell to $5.40 million from $5.72 million. However, operating expenses increased modestly to $2.43 million, while research and development spending rose slightly to $463,644 from $456,779. Despite cost controls in certain areas, the reduction in revenue outweighed these improvements, leading to a notable contraction in profitability. On the balance sheet side, total assets decreased to $13.11 million at year-end 2025 from $13.80 million in 2024. Stockholders’ equity also declined to $11.23 million from $11.88 million, reflecting the lower earnings base. Meanwhile, current liabilities decreased to $1.67 million from $1.91 million, indicating some improvement in short-term obligations. Management attributed the year-over-year decline primarily to weakness in the company’s cosmetic ingredients segment. President Donna Vigilante highlighted that excess inventory held by the company’s largest distributor, Ashland Specialty Ingredients, led to reduced order volumes throughout the year. Additionally, global demand softness — particularly in China — further pressured sales, compounded by increased competition from local Asian producers and the impact of tariffs. Despite these headwinds, management pointed to several pos...

HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025. Donna Vigilante, President of United-Guardian, stated, “Our financial performance in 2025 was primarily impacted by the decrease in sales of our cosmetic ingredients. One of the issues we faced was excess inventory held by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). The inventory overstock led to reduced order quantities from ASI throughout the year. The situation was further impacted by decreased global demand for our products, particularly in China, where heightened competition from local Asian producers, and the impact of global tariffs, negatively impacted sales. In response to these challenges, we have been collaborating closely with our distributor in China to regain lost market share, offering competitive pricing where feasible, differentiating our products from the competition, and exploring new markets where cost pressures are less pronounced.” “On a positive note, sales of pharmaceuticals and medical lubricants increased in 2025 compared to 2024, by 15% and by 4%, respectively. The increase in medical lubricants was driven by greater demand from two of our large contract manufacturer customers in China. The increase in pharmaceutical sales resulted from an increase in sales to all three of our national drug wholesalers, combined with a decrease in Medicare rebates. In 2025 we initiated a new marketing strategy to expand the domestic sales of Renacidin® by increasing awareness of Renacidin and seeking its inclusion on additional drug formularies. I am happy to report that we recently received approval from two major pharmacy benefit managers. We believe that having Renacidin available on additional drug formularies will enhance patient access and will support the product’s long-term commercial growth. We are optimistic that this initiative, along with the new marketing and distribution agreements we entered into in 2025 for our cosmetic ingredients, will result in increased sales in the coming years.” United-Guardian is a manufacturer of cosmetic i...

HAUPPAUGE, N.Y. (AP) — HAUPPAUGE, N.Y. (AP) — United-Guardian Inc. (UG) on Friday reported net income of $650,000 in its fourth quarter. The Hauppauge, New York-based company said it had net income of 14 cents per share. The cosmetic ingredients maker posted revenue of $3 million in the period. For the year, the company reported profit of $2.1 million, or 46 cents per share. Revenue was reported as $10.5 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UG at https://www.zacks.com/ap/UG

HAUPPAUGE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2025. Sales for the nine-month period ended September 30th decreased from $9,705,262 in 2024 to $7,583,613 in 2025 and net income decreased from $2,747,151 ($0.60 per share) to $1,456,162 ($0.32 per share). Third quarter sales decreased from $3,060,113 in 2024 to $2,264,261 in 2025 and net income decreased from $865,484 ($0.19 per share) to $268,441 ($0.06 per share). Donna Vigilante, President of United-Guardian, stated, “While sales of our pharmaceutical and medical products both increased during the first nine-months of 2025 compared with the same period in 2024 (increasing by 10% and 6%, respectively), we did experience a decrease in sales of our cosmetic ingredients in this year’s third quarter compared with 2024. That decrease was attributable primarily to reduced purchases of our cosmetic ingredients by Ashland Specialty Ingredients (“ASI”), our largest marketing partner, which has been dealing with difficult tariff and geopolitical concerns in Asia that have caused some customers to move towards lower cost local products. This has resulted in ASI having to work down excess inventory, which has caused a decrease in their orders this year. This is consistent with recent reports that indicated that sales and earnings of U.S. chemical companies in the third quarter were depressed mainly due to weak China demand, continued destocking, and tariffs. ASI has indicated to us that it is confident that it will be able to regain market share by offering more competitive pricing going forward.” “On a positive note we have made progress with our project to increase sales of Renacidin®, our most important pharmaceutical product, by working with an outside pharmaceutical consultant to have Renacidin included on additional drug formularies. We are excited about the potential this project has to significantly increase sales of Renacidin over the coming years. We are hopeful that this project, along with the new marketing agreements we have negotiated recently for some of our new personal care products, will give us an excellent opportunity to increase our revenue in the coming years. United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness...

HAUPPAUGE, N.Y. (AP) — HAUPPAUGE, N.Y. (AP) — United-Guardian Inc. (UG) on Thursday reported profit of $268,000 in its third quarter. On a per-share basis, the Hauppauge, New York-based company said it had net income of 6 cents. The cosmetic ingredients maker posted revenue of $2.3 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UG at https://www.zacks.com/ap/UG

Shares of United-Guardian UG have risen 1.5% since reporting second-quarter 2025 results, trailing the S&P 500 index’s 1.8% growth. However, over the past month, the stock has fallen 0.6%, underperforming the broader index’s 3.2% advance. This relative weakness over the month contrasts with its modest post-earnings uptick. For the three months ended June 30, 2025, United-Guardian posted net sales of $2.84 million, down 16.3% from $3.39 million a year earlier. Net income fell 34.5% year over year to $626,826, or 14 cents per share, from $956,225, or 21 cents per share. On a six-month basis, net sales declined 20% to $5.32 million from $6.65 million in the prior-year period, while net income slid 36.9% to $1.19 million, or 26 cents per share, from $1.88 million, or 41 cents per share. United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote Cost of sales as a percentage of net sales increased to 47% in the second quarter of 2025 from 46% in the year-ago quarter. Operating expenses rose 15.1% to $694,050 in the quarter, driven by higher marketing and selling costs. Research and development (R&D) expenses were relatively stable, slipping 3.4% to $107,868. Investment income for the quarter totaled $70,573, down from $100,007 in the same period of 2024, while the company booked a $24,576 net gain on marketable securities against a $9,501 loss a year ago. Sales performance varied significantly by product category. For the first half of 2025, sales of pharmaceuticals grew 11%, and medical lubricants rose 12% from the prior-year period. However, cosmetic ingredient sales dropped sharply due to reduced orders from the company’s largest distributor, Ashland Specialty Ingredients (“ASI”), which faced an inventory overstock, led by softer demand in Asia. Management indicated that efforts are underway to resolve the overstock and recover sales momentum in the second half of the year. President Donna Vigilante noted that the pharmaceutical and medical lubricant categories provided a measure of resilience in an otherwise weaker sales environment. The company is pursuing a strategic initiative to have Renacidin, its most important pharmaceutical product, added to additional drug formularies, a move expected to meaningfully boost sales in the coming years. Management acknowledged the cosmetic segment’s weakness but expressed optimism that resolvi...

Explore United-Guardian's Fair Values from the Community and select yours Revenue: US$2.84m (down 16% from 2Q 2024). Net income: US$626.8k (down 34% from 2Q 2024). Profit margin: 22% (down from 28% in 2Q 2024). The decrease in margin was driven by lower revenue. EPS: US$0.14 (down from US$0.21 in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period United-Guardian shares are down 1.4% from a week ago. You should always think about risks. Case in point, we've spotted 4 warning signs for United-Guardian you should be aware of, and 3 of them make us uncomfortable. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

HAUPPAUGE, N.Y. (AP) — HAUPPAUGE, N.Y. (AP) — United-Guardian Inc. (UG) on Friday reported earnings of $627,000 in its second quarter. The Hauppauge, New York-based company said it had net income of 14 cents per share. The cosmetic ingredients maker posted revenue of $2.8 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UG at https://www.zacks.com/ap/UG

HAUPPAUGE, N.Y., Aug. 08, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2025. Second quarter net sales decreased from $3,390,205 in 2024 to $2,838,225 in 2025, with net income decreasing from $956,225 ($0.21 per share) to $626,826 ($0.14 per share). As compared with the first quarter of 2025, the second quarter net sales increased by 14% and net income increased by 12%. Net sales for the six-month period ended June 30th decreased from $6,645,149 in 2024 to $5,319,352 in 2025 and net income decreased from $1,881,667 ($0.41 per share) to $1,187,721 ($0.26 per share). Donna Vigilante, President of United-Guardian, stated, “Sales of our pharmaceuticals and medical lubricants both increased for the first half of 2025 compared with the same period in 2024. Sales of our medical lubricants increased by 12% and pharmaceutical product sales increased by 11% in the first six months of 2025 compared with the same period in 2024. Those increases were offset by a decrease of sales of our cosmetic ingredients in the first six months of 2025 compared with the same period in 2024. This decrease was attributable to reduced purchases by Ashland Specialty Ingredients (“ASI”), our largest cosmetic distributor. The primary reason for the decrease in purchases by ASI was softer demand in Asia, which resulted in an inventory overstock situation that ASI had to work down before it could increase its purchases. We are working closely with ASI and are hopeful that cosmetic sales will improve in the second half of the year as this overstock situation is resolved. We are also initiating a new project to have Renacidin®, our most important pharmaceutical product, included in additional drug formularies. If this project is successful, we should be able to significantly increase sales of Renacidin over the coming years.” United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “saf...